Specific gut microbiome members are associated with distinct immune markers in pediatric allogeneic hematopoietic stem cell transplantation by Ingham, Anna Cäcilia et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Specific gut microbiome members are associated with distinct immune markers in
pediatric allogeneic hematopoietic stem cell transplantation
Ingham, Anna Cäcilia; Kielsen, Katrine; Cilieborg, Malene Skovsted; Lund, Ole; Holmes,
Susan; Aarestrup, Frank M.; Müller, Klaus Gottlob; Pamp, Sünje Johanna
Published in:
Microbiome
DOI:
10.1186/s40168-019-0745-z
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Ingham, A. C., Kielsen, K., Cilieborg, M. S., Lund, O., Holmes, S., Aarestrup, F. M., ... Pamp, S. J. (2019).
Specific gut microbiome members are associated with distinct immune markers in pediatric allogeneic
hematopoietic stem cell transplantation. Microbiome, 7, [131]. https://doi.org/10.1186/s40168-019-0745-z
Download date: 27. May. 2020
RESEARCH Open Access
Specific gut microbiome members are
associated with distinct immune markers in
pediatric allogeneic hematopoietic stem
cell transplantation
Anna Cäcilia Ingham1,7, Katrine Kielsen2,3, Malene Skovsted Cilieborg4, Ole Lund5, Susan Holmes6,
Frank M. Aarestrup1, Klaus Gottlob Müller2,3 and Sünje Johanna Pamp1*
Abstract
Background: Increasing evidence reveals the importance of the microbiome in health and disease and inseparable
host-microbial dependencies. Host-microbe interactions are highly relevant in patients receiving allogeneic
hematopoietic stem cell transplantation (HSCT), i.e., a replacement of the cellular components of the patients’
immune system with that of a foreign donor. HSCT is employed as curative immunotherapy for a number of non-
malignant and malignant hematologic conditions, including cancers such as acute lymphoblastic leukemia. The
procedure can be accompanied by severe side effects such as infections, acute graft-versus-host disease (aGvHD),
and death. Here, we performed a longitudinal analysis of immunological markers, immune reconstitution and gut
microbiota composition in relation to clinical outcomes in children undergoing HSCT. Such an analysis could reveal
biomarkers, e.g., at the time point prior to HSCT, that in the future could be used to predict which patients are of
high risk in relation to side effects and clinical outcomes and guide treatment strategies accordingly.
Results: In two multivariate analyses (sparse partial least squares regression and canonical correspondence analysis),
we identified three consistent clusters: (1) high concentrations of the antimicrobial peptide human beta-defensin 2
(hBD2) prior to the transplantation in patients with high abundances of Lactobacillaceae, who later developed
moderate or severe aGvHD and exhibited high mortality. (2) Rapid reconstitution of NK and B cells in patients with
high abundances of obligate anaerobes such as Ruminococcaceae, who developed no or mild aGvHD and exhibited
low mortality. (3) High inflammation, indicated by high levels of C-reactive protein, in patients with high
abundances of facultative anaerobic bacteria such as Enterobacteriaceae. Furthermore, we observed that antibiotic
treatment influenced the bacterial community state.
Conclusions: We identify multivariate associations between specific microbial taxa, host immune markers, immune
cell reconstitution, and clinical outcomes in relation to HSCT. Our findings encourage further investigations into
establishing longitudinal surveillance of the intestinal microbiome and relevant immune markers, such as hBD2, in
HSCT patients. Profiling of the microbiome may prove useful as a prognostic tool that could help identify patients
at risk of poor immune reconstitution and adverse outcomes, such as aGvHD and death, upon HSCT, providing
actionable information in guiding precision medicine.
Keywords: Gut microbiota, Pediatric cancer, HSCT, 16S rRNA gene profiling, Data integration, Immune
reconstitution, Ruminococcaceae, Human beta-defensin 2, acute GvHD, B cells and NK cells
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Background
The microbiome has gained increasing attention as a crucial
contributor in the course of various diseases, and as target
of treatment [1–3]. A number of complications in allogeneic
hematopoietic stem cell transplantation (HSCT) have re-
cently been associated with the gut microbiota [4, 5]. HSCT
is a curative treatment for various hematologic diseases in-
cluding malignancies, such as acute lymphoblastic leukemia
(ALL), as well as non-malignant diseases, such as metabolic
disorders and immune deficiency syndromes [6]. One goal
of HSCT is achieving a beneficial graft-versus-leukemia
(GvL) effect where donor-derived T lymphocytes and
natural killer cells target leukemic cells in the recipient [7].
Prior to allogeneic HSCT, the patients undergo a preparative
conditioning regimen involving combinations of chemother-
apeutic agents and total body irradiation (TBI) [8] to
eradicate leukemic cells and induce immunosuppression.
Immunosuppressive treatment (both prior to and post-
HSCT) in the stem cell recipient prevents a graft-versus-
host reaction caused by cytotoxic donor T lymphocytes that
attack healthy cells in the recipient [8]. To limit infectious
diseases due to immunosuppression, the patients are admin-
istered broad-spectrum antibacterial and antifungal com-
pounds. Subsequently, the patients receive a stem cell graft
originating from the bone marrow, peripheral blood or um-
bilical cord blood of a human leukocyte antigen (HLA)-
matched sibling donor or an unrelated donor (i.e., allogeneic
HSCT) [9, 10].
In patients undergoing HSCT, it has been previously ob-
served that there are associations between the microbiome
and clinical outcomes such as acute graft-versus-host dis-
ease (aGvHD) [5, 11, 12] and survival [4, 13]. GvHD after
HSCT has been related to an expansion of the order Lacto-
bacillales, especially Enterococcus spp. [11] and Lactobacil-
lus spp. [14] and a loss of Clostridiales [14]. However, so
far, few studies have monitored the microbiome longitudin-
ally [11, 14, 15]. This indicates the need for more detailed
investigations that take temporal monitoring of both the
host immune system and the microbiome into account.
Several markers of the host immune system, including
inflammatory markers (such as C-reactive protein (CRP)
and interleukin 6 (IL-6)) and markers of intestinal tox-
icity (such as plasma citrulline), have been studied in
HSCT [16, 17]. Potential novel markers, such as anti-
microbial peptides (AMPs), have also been proposed to
be involved in outcomes after HSCT, for example in
immunomodulation and regulation of microbial homeo-
stasis [18]. AMPs, especially defensins such as human
beta-defensin 2 and 3 (hBD2 and hBD3), have previously
been found to play a role in some inflammatory diseases
[19, 20]. However, to our knowledge, AMPs have not yet
been employed as markers in the context of HSCT. An in-
teresting research question remains: How are known and
novel markers within the host immune system associated
with each other or with changes in the microbiome? A
better understanding about these associations would pro-
vide a more holistic insight into the underlying mecha-
nisms affecting clinical outcomes after HSCT.
Another crucial factor impacting on complications and
clinical outcomes after HSCT is immune reconstitution.
Immune reconstitution involves the essential cellular
components of the adaptive immune system, namely T
and B cells, as well as key cellular components of the in-
nate immune defense, namely natural killer (NK) cells,
monocytes, and neutrophils [21]. A microbial influence
on immune cell differentiation has been observed previ-
ously, e.g., commensal Clostridiales were found to regu-
late Treg cell differentiation in the colon [22]. Therefore,
an influence of the intestinal microbiome on immune re-
constitution following HSCT is likely, but had not been
investigated prior to this study.
Here, we monitor both host factors and the intestinal
microbiome longitudinally. We included markers of in-
flammation (CRP and IL-6) and intestinal toxicity
(plasma citrulline) as well as the antimicrobial peptides
(hBD2 and 3), which in the following sections are col-
lectively referred to as immune markers. To assess the
prognostic potential of immune markers associated with
gut microbial dynamics for immune reconstitution and
clinical outcomes after HSCT (aGvHD and survival) in a
holistic way, we implemented multivariate multi-table
(also referred to as multi-way) approaches. This facili-
tated the integration of a variety of different factors that
could influence the patients’ convalescence. We reveal
distinct clusters of bacteria associated with sets of im-
mune markers and clinical outcomes. Patients with rapid
NK and B cell reconstitution that had no or mild aGvHD
and low mortality exhibited high abundances of members
belonging to the family of Ruminocaccaceae. In contrast,
patients with moderate to severe aGvHD and high mortal-
ity showed high plasma concentrations of the antimicrobial
peptide hBD2 already prior to HSCT. In these patients, we
observed increased Lactobacillaceae abundances.
Results
To assess associations between immune markers and gut
microbial dynamics in the context of immune reconstitu-
tion and clinical outcomes after HSCT, we monitored 37
children over time undergoing allogeneic HSCT (Fig. 1a,
Additional file 1: Table S1). We gained insight into the pa-
tients’ immune reconstitution by determining T, B, NK,
monocyte, and neutrophil cell counts in peripheral blood
(Fig. 1a). We measured C-reactive protein (CRP) and
plasma interleukin 6 (IL-6) as markers of inflammation,
and human beta-defensin 2 and 3 (hBD2 and 3) as
markers for potential innate immune activation and sys-
temic infection (Fig. 1a, Additional file 1: Table S1).
Plasma citrulline levels were measured as a marker of
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intestinal toxicity, being produced selectively by function-
ing enterocytes. To relate immune marker levels to mem-
bers of the intestinal microbiota in patients undergoing
HSCT, we characterized the longitudinal dynamics of the
human intestinal microbiome in a subset of 30 patients by
utilizing 16S rRNA gene profiling (Fig 1a).
Patient cohort and outcomes
At the time of HSCT, the 37 patients were on average 8.2
years old (age range 1.1–18.0 years). Twenty-five patients
(68%) were diagnosed with at least one bacterial infection
at median 75 days post-HSCT (range day − 19 to + 668).
Twenty-six patients (70%) had no or mild aGvHD (grade
0–I) (Additional file 1: Table S1). Eleven patients (30%)
developed moderate to severe aGvHD (grade II, III, or IV)
at median 18 days (range day + 9 to + 45) after transplant-
ation (Additional file 1: Table S1). Seven patients (19%)
died during the follow-up period at median 266 days post-
HSCT (range day + 9 to + 784) (five relapse-related and
two treatment-related deaths) (Additional file 1: Table S1).
In total, six patients (16%) relapsed, four of which under-
went a re-transplantation. All patients received antibiotics
pre- and post-transplantation (Additional file 1: Table S1).
Prophylactic trimethoprim-sulfamethoxazole was admin-
istered to all patients from day − 7 until transplantation.
During the period of neutropenia or latest from day − 1,
patients received prophylactic intravenous ceftazidime. In
case of infections indicated by fever or microbial culture,
ceftazidime was substituted by intravenous meropenem,
vancomycin, or other antibiotics, according to culture-
based results.
Temporal dynamics of immune markers and the intestinal
microbiota in HSCT patients
Prior to assessing the interplay between clinical variables
(i.e., immune markers, immune reconstitution, clinical
outcomes) and the intestinal microbiota, we character-
ized these components separately. In order to provide an
overview of changes in immune markers and immune cell
counts after HSCT in our cohort (n = 37), we assessed their
temporal patterns (Fig. 1b, and Additional file 2: Figure S1).
Of note, these supplemental univariate analyses mainly
served the purpose of visually aiding our subsequent
multivariate analyses approaches (Additional file 3: Figure
S2). We characterized hBD2 for the first time in the context
of HSCT by assessing plasma hBD2 concentrations over
time from pre-HSCT to month + 3 post-HSCT in patients
compared to healthy controls. The hBD2 concentration dif-
fered significantly between time points (P < 0.001, Kendall’s
W = 0.6). It increased from pre-HSCT to the day of HSCT
(P < 0.001), then slightly decreased in week + 1 (P = 0.038)
before increasing again in week + 3 (P = 0.006) (Fig. 1b).
HBD2 decreased again in month + 2 (P = 0.014) (Fig. 1b).
CRP levels differed significantly between time points (P <
0.001, Kendall’s W = 0.33). They were high pre-HSCT and
until week + 2, then decreasing significantly in week + 3 (P
< 0.001) with the lowest levels in weeks + 4 to + 6 (P <
0.001) (Additional file 2: Figure S1A). Median plasma cit-
rulline levels were significantly different between time
points (P < 0.001, Kendall’sW = 0.32). They decreased from
pre-HSCT to week + 1 (P < 0.001) and increased again in
week + 3 (P < 0.001) (Additional file 2: Figure S1A). B cell
counts (Kendall’s W = 0.5) as well as CD4+ T cell counts
(Kendall’s W = 0.46) increased steadily from month + 1 to
month + 6 (P < 0.001) (Additional file 2: Figure S1B).
To gain insight into intestinal microbial dynamics
before, at the time of, and after HSCT, we obtained a
total of 97 fecal samples from a subcohort of 30 pa-
tients. Using 16S rRNA gene sequence analysis, we
identified 239 operational taxonomic units (OTUs)
(see “Methods” section). Microbial alpha-diversity was
lower at all time points post-HSCT compared to pre-
HSCT (Fig. 1c). The median inverse Simpson index
decreased from 3.27 (range 1.02–7.4) before HSCT to
2.89 (range 1.04–10.77) on the day of transplantation
and further to 2.03 (range 1.0–16.51) post-HSCT
(median of week + 1 to + 5) (Fig. 1c). When assessing
the relative abundances of the eight most abundant
taxonomic families over time, we observed a reduc-
tion in Lachnospiraceae and Ruminococcaceae abun-
dances immediately after HSCT from 20.1 and 9.6%,
respectively before HSCT to 6.1% and 1.7% on aver-
age in weeks + 1 to + 5 (Fig. 1d). In contrast, Entero-
coccaceae abundances rose from 17.4% before
transplantation to 30.2% on average in weeks + 1 to
+ 5 (Fig. 1d).
(See figure on previous page.)
Fig. 1 Monitoring of the host immune system and intestinal microbiome in hematopoietic stem cell transplantation (HSCT). a Study outline. A
cohort of 37 pediatric recipients of allogeneic HSCT was monitored prior to HSCT, at the time point of HSCT, and post-HSCT (median follow-up
time 5.2 years). A range of patient characteristics as well as disease outcomes, immune markers, immune cell counts, and intestinal patterns of
microbial community composition were recorded at the noted time points (up to 12 months post-HSCT). See Table S1 for details regarding the
patient characteristics. b Plasma hBD2 concentrations over time and in comparison to healthy controls (young adults). The y-axis was log10-
transformed for better visualization. Zeros were replaced with 1 to avoid undefined values on the log-transformed axis. Asterisks indicate whether
the concentrations at each respective time point were significantly different from any of the other time points (showing the maximum
significance level). c Bacterial alpha-diversity, measured by inverse Simpson index, of the intestinal microbiome shown with log10-transformed y-
axis. d Relative abundances over time of the 8 most abundant taxonomic families in the dataset (comprising 98 fecal samples). *P < 0.05; **P <
0.01; and ***P < 0.001
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Associations between immune markers and immune cell
reconstitution in HSCT patients
In order to identify patient baseline parameters and clin-
ical outcomes (e.g., aGvHD, relapse, overall survival), as
well as immune markers and immune cell types that
might be important determinants in HSCT in relation to
the microbiome, we performed variable assessment by
permutational multivariate analysis of variance (adonis).
The variables that were found to be significant (P ≤ 0.05),
i.e., those that explained most variation in the microbial
community distance matrix, were selected for subsequent
analyses (Additional file 3: Figure S2, Additional file 4:
Table S2). Of note, the occurrence of relapse as an indica-
tion of transplantation outcome was assessed but not
found to be significant in adonis, and was therefore not in-
cluded in follow-up analyses. We then assessed associa-
tions of the selected immune markers and immune cells
in the data set comprising 37 patients by determining
Spearman’s rank correlations. The hBD2 concentrations
pre-HSCT, on the day of HSCT and in weeks + 1 and + 2
post-HSCT were positively correlated with each other (ρ
= 0.73–1, P < 0.001) (Fig. 2a). NK cell counts in month +
1 exhibited a positive correlation with total B cell counts
(ρ = 0.64, P = 0.0046) and mature B cells counts (ρ = 0.62,
P = 0.0114) in month + 2. When we related immune cell
reconstitution to outcomes, we observed significantly
higher NK cell counts and total B cell counts in month +
2 in patients with no or mild aGvHD (grade 0–I) com-
pared with patients with moderate to severe aGvHD
(grade II–IV) (Wilcoxon rank sum test, NK cells, P =
0.011; B cells, P < 0.001) (Fig. 2b).
High plasma hBD2 and monocytes prior to HSCT in
patients with high Lactobacillaceae
To gain insight into how the selected immune markers
and immune cell counts co-vary with gut microbial
abundances in patients with distinct outcomes, we im-
plemented two multivariate multi-table approaches for
the subcohort (n = 30), namely sparse partial least
squares (sPLS) regression and canonical correspondence
analysis (CCpnA). The sPLS regression models OTU
abundances as predictors and clinical variables as re-
sponse variables and explains the latter in an asymmetric
(i.e., unidirectional) way. In contrast, the CCpnA as-
sesses relationships between parameters of the immune
system and microbiota bidirectionally. In the following
paragraphs, the results of these two analyses are re-
ported for one observed cluster at a time, respectively.
Fig. 2 Correlations between immune markers, immune cell counts, and outcomes in patients undergoing HSCT. a Pairwise Spearman’s
correlation between immune markers and immune cell counts in HSCT patients (n = 37) that were determined to be significant in a
permutational multivariate analysis of variance using (microbial) distance matrices (adonis) (See Table S2). Positive and negative correlations are
represented by red or blue circles, respectively, and the size of circles and intensity of color refer to the strength of the correlation. Correlations
that are significant (P ≤ 0.05) are indicated by a black outline of the circle. b Natural killer (NK) and total B cell (mature and immature)
reconstitution in month + 2 with respect to the maximum acute GvHD (aGvHD) grade (0–I vs. II–IV) in HSCT patients (n = 37). hBD2_pre,
hBD2_w0, hBD2_w1, hBD2_w2 plasma human beta-defensin 2 concentration pre-HSCT, on the day of HSCT, and in weeks + 1 and + 2,
respectively; mono_pre, mono_w3 monocyte counts pre-HSCT and in week + 3, respectively; neutro_m3 neutrophil count in month + 3; CD8+_m1
CD8+ T cell counts in month + 1; Age recipient age at time point of transplantation; NK_m1, NK_m2 natural killer cell counts in months + 1 and +
2, respectively; B_m2, mat_B_m2, immat_B_m2 all, mature, and immature B cell counts in month + 2; CD4+_m2 CD4+ T cell counts in month + 2;
Citr_pre, Citr_w1 plasma citrulline levels pre-HSCT and in week + 1, respectively; CRP, CRP_w1, CRP_w5, CRP_w6, CRP_m3, CRP_m6 C-reactive
protein levels at time points simultaneous to microbiome characterization, in weeks + 1, + 5, and + 6, and in months + 3 and + 6, respectively. *P
< 0.05; **P < 0.01, and ***P < 0.001
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First, we performed sPLS regression to reveal multi-
variate correlation structures between immune markers,
immune cell counts, and OTU abundances, modeling
the latter as explanatory variables. The sPLS regression
and subsequent hierarchical clustering suggested that
the data separated into three clusters (Fig. 3a). High
monocyte counts and high plasma hBD2 concentration
prior to HSCT, high patient age at the time of trans-
plantation, and high abundances of Lactobacillaceae in-
dependent of time point contributed the most to the
formation of cluster 1. Of note, monocyte counts and
hBD2 were positively correlated with each other, in
agreement with the correlation analysis above (Fig. 2a).
The Lactobacillaceae were represented by microaerophilic
Lactobacillus sp. OTUs (e.g., AF413523.1, GU451064.1,
KF029502.1) (Fig. 3b, Additional file 5: Table S3). These
OTUs exhibited high loading weights in sPLS dimension 2
(Fig. 3c), indicating that they contributed strongly to the
separation of clusters in dimension 2 (Fig. 3a, b).
Second, we applied CCpnA to model the canonical re-
lationships between OTU abundances and clinical vari-
ables through the construction of common “latent”
variables. The CCpnA confirmed the separation of the
data into three clusters as observed in the sPLS regres-
sion (Figs. 3a, 4, and Additional file 6: Figure S3A), in-
cluding the clustering of OTUs. In addition, the CCpnA
facilitated the inclusion of categorical variables, such as
the patients’ baseline parameters (e.g., recipient sex,
donor type) and clinical endpoints (aGvHD grade, over-
all survival). Because CCpnA is an unsupervised method
and upheld the results of the sPLS regression, it provides
confidence in the cluster findings.
Cluster 1 in the CCpnA seemed to include patients who
developed moderate to severe aGvHD (grade II–IV) and
who died. As suggested by both, sPLS and CCpnA, these
patients exhibited high levels of plasma hBD2 before
HSCT (and in week + 1 and + 2) and high monocyte
counts before HSCT. OTUs within this CCpnA cluster
predominantly included members of the family Lactoba-
cillaceae and were most abundant in fecal samples of
these patients (Fig. 4 and Additional file 7: Figure S4).
OTUs that were assigned to cluster 1 by the sPLS-based
hierarchical clustering were congruently associated with
the same clinical variables in the CCpnA (Figs. 3b and 4).
Temporal patterns of the Lactobacillaceae-dominated
community state type
Upon revealing an association between high plasma
hBD2 concentrations and monocyte counts prior to
HSCT, moderate to severe aGvHD, and high mortality
with high abundances of Lactobacillaceae in multivariate
analyses, we assessed in more detail the importance of
longitudinal changes in these components. We imple-
mented an additional approach to identify distinct bacterial
community patterns by employing partitioning around
medoid (PAM) clustering (see “Methods” section). In this
analysis, we detected four community state types (CSTs).
Dominating taxa, similar to those identified by the sPLS-
based hierarchical clustering, were revealed in the CSTs,
e.g., Lactobacillaceae members dominated CST 1 (Add-
itional file 5: Table S3 and Additional file 8: Figure S5). We
then used this information to examine temporal commu-
nity state changes in individual patients, i.e., their transi-
tions between CSTs over the course of time (Fig. 5). Based
on clinical outcomes, the patients can be divided into four
groups: (1) patients who developed no or mild aGvHD
(aGvHD grade 0–I) and survived compared to (2) patients
who died, and (3) patients who developed moderate to se-
vere aGvHD (grade II–IV) and survived compared to (4)
patients who died (Fig. 5). We observed that six out of eight
patients (75%) with moderate to severe aGvHD (groups 3
and 4) harbored the Lactobacillaceae-dominated CST 1 at
least once during the monitored period (1×: n = 2, 2×: n =
2, 3×: n = 2) (Fig. 5). In comparison, only five out of 22 pa-
tients (23%) with aGvHD grade 0–I (groups 1 and 2) car-
ried CST 1 one or two times (Fig. 5). Interestingly, high
abundances of Lactobacillaceae in patients with aGvHD
grade II–IV (groups 3 and 4) occurred predominantly at
late time points (week + 1 and later) (Fig. 5 and Additional
file 7: Figure S4).
Temporal association of Lactobacillaceae with aGvHD and
immune markers
To relate temporal changes in immune markers to those
in the bacterial community composition in patients with
aGvHD grade II–IV who died (group 4), we assessed
their individual longitudinal profiles (Fig. 6). In all three
patients (P24, P26, P30), a large expansion of Lactobacilla-
ceae abundances after the onset of aGvHD was observed.
The average relative abundance of Lactobacillaceae after
aGvHD onset was 72.92% (range 0.22–97.04%), as com-
pared to before aGvHD (average 9.88%, range 0.25–
37.83%) (Fig. 6). Furthermore, bacterial alpha diversity was
lower at the time point after aGvHD onset compared to
the time point before (Fig. 6). All three patients were
treated with antibiotics for different durations between
these two time points and prior to the time point before
aGvHD onset.
In agreement with the results of the multivariate ana-
lyses, two of the patients (P24 and P26) exhibited between
1.95- and 14.56-times higher plasma hBD2 concentrations
for all measured time points compared with the average of
the whole data set (average plasma hBD2 concentration:
10,983.9 pg/ml, range 0–177,400.28 pg/ml). The plasma
hBD2 concentration was the highest at the time of HSCT
in patient P26 and before HSCT in patient P24 (Fig. 6). Of
note, patient P24 received corticosteroid-based GvHD
prophylaxis prior to HSCT and both patients received
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anti-thymocyte globulin (ATG) as part of their condition-
ing regimen. These two patients had underlying malignant
diseases and their pre-HSCT CRP levels, providing insight
into underlying inflammation, were 1.6 times lower and
1.29 times higher, respectively, compared with the average
of the whole data set on that time point (average plasma
CRP concentration before HSCT: 19.21 mg/L, range 1–
60.36 mg/L), respectively. Monocyte counts before HSCT,
i.e., recipient-derived cells, were 6.25 times higher in pa-
tient P24 compared with the average of the whole data set
(average monocyte count before HSCT: 0.45 × 109/L,
range 0.08–2.83 × 109/L) and close to average in patient
P26. In both patients, monocyte counts were higher before
(i.e., recipient-derived cells) than after HSCT (i.e., donor-
derived cells) (Fig. 6).
In contrast to the Lactobacillaceae expansion after
aGvHD onset in group 4, we observed high Lactobacilla-
ceae abundances already before aGvHD onset in three
survivors (P16, P22, and P29) who developed aGvHD
grade II–IV (group 3) (Additional file 9: Figure S6). The
average relative abundance of Lactobacillaceae before
aGvHD onset was 53.18% (range 0.35–98.86%), as com-
pared to after aGvHD (average 18.25%, range 0–54.78%).
However, these observations were limited by a small
number of patients per outcome group (groups 3 and 4)
(Fig. 5) and therefore cannot serve to provide statistical
evidence.
High NK and B cells and no or mild aGvHD in patients
with high obligate anaerobes such as Ruminococcaceae
The association between NK and total B cell counts after
HSCT observed in the Spearman’s correlation analysis
(Fig. 2) was supported by the multivariate analyses (Figs.
3 and 4). In the sPLS regression, cluster 2 included high
NK cell counts in months + 1 and + 2, as well as high
immature, mature, and total B cell counts in month + 2
(Fig. 3a). Furthermore, NK and B cell counts were posi-
tively correlated with OTUs found in cluster 2 (Fig. 3a,
b), in particular with members of the family Ruminococ-
cacea (Order: Clostridiales) (Fig. 3b, Additional file 5:
Table S3). Strong positive correlations between mature
and total B cell counts in month + 2 and NK cell counts
in month + 1 were observed, for example, with Faecali-
bacterium sp. (DQ804549.1) (Fig. 3b, c, Additional file 5:
Table S3). Additionally, we observed positive associa-
tions of these immune cells with Lachnospiraceae
(Order: Clostridiales), among those two Blautia spp.
(DQ800353.1 and DQ802363.1) (Fig. 3b, c, Additional
file 5: Table S3).
In support of the sPLS regression, the CCpnA also re-
vealed high NK and B cell counts in cluster 2 in months
+ 1 and + 2. Based on the CCpnA, we found that NK
and B cell reconstitution was associated with certain dis-
ease outcomes. For example, patients who had no or
mild aGvHD and survived were predominantly repre-
sented in cluster 2. Cluster 2 included OTUs mainly be-
longing to Ruminococcaceae and Lachnospiraceae,
exhibiting their highest abundances in patient samples
associated with this cluster. OTUs with the highest
scores in dimension 2 predominantly belonged to the
family of Ruminococcacea and matched the sPLS-based
hierarchical cluster assignment (Fig. 4).
As all patients received antibiotic treatment prior to and
post-transplantation, we examined the potential effect of
antibiotics on the intestinal bacterial community compos-
ition. A trending influence of the vancomycin treatment
was revealed by adonis analysis (P = 0.055). Using a
CCpnA model that also included information about anti-
biotic treatments, we found that patients exhibited higher
abundances of Ruminococcaceae and Lachnospiraceae and
lower abundances of Enterobacteriaceae at time points
without the vancomycin treatment compared to with
vancomycin (Additional file 6: Figure S3B). The same pat-
tern was observed for treatment with ciprofloxacin (Add-
itional file 6: Figure S3B).
Community state typing also revealed a state type
dominated by Ruminococcaceae and Lachnospiraceae
family members (CST 2) (Additional file 8: Figure S5). A
total of ten out of 22 patients (45%) with no or mild
aGvHD were assigned to CST 2 at least at one time
(See figure on previous page.)
Fig. 3 Sparse partial least squares (sPLS) regression of immune parameters and intestinal bacterial taxa during HSCT. a Correlation circle plot for
the first two sPLS dimensions with correlations displayed for > 0.2/< − 0.2. The two grey circles indicate correlation coefficient radii at 0.5 and 1.0.
Bacterial operational taxonomic units (OTUs) are displayed as circles, and are colored according to the cluster they are affiliated with (cluster 1:
blue; cluster 2: orange; cluster 3: grey). Variables projected closely to each other are positively correlated. Variables projected diametrically
opposite from each other are negatively correlated. Variables situated perpendicularly to each other are not correlated. The variance explained by
the OTUs is 4.12% on component 1, and 4.79% on component 2. The variance explained by the clinical variables is 16.1% on component 1, and
17.19% on component 2. b Clustered image map (CIM) of the first two sPLS dimensions, displaying pairwise correlations between OTUs (bottom)
and clinical variables (left). Red and blue indicate positive and negative correlations, respectively. Hierarchical clustering (clustering method:
complete linkage, distance method: Pearson’s correlation) was performed within the mixOmics cim() function based on the sPLS regression
model. An overview of the OTU abundances in the individual samples is provided in Figure S3, and a list of the individual OTUs and their cluster-
affiliation is provided in Table S3. c Loading plots of OTUs with maximum contributions on the first (left) and second (right) component,
respectively. The bars are colored according to the cluster they are affiliated with. The family-affiliation for each respective OTU is indicated by
color (for legend see b). Abbreviations of variables are the same as in Fig. 2
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Fig. 4 Canonical correspondence analysis (CCpnA) of immune parameters and intestinal bacterial taxa in patients undergoing HSCT. Triplot
showing dimension 1 and 2 of the CCpnA that included continuous clinical variables (arrows), categorical variables (+), and OTUs (circles).
Samples are depicted as triangles. OTUs with a correlation of > 0.2/< − 0.2 in the sPLS analysis were included in the CCpnA model. Only the
variables and OTUs with a score > 0.2/< − 0.2 in at least one CCpnA dimension are shown. The OTUs in the CCpnA plot are colored according to
the cluster they were affiliated with in the sPLS-based hierarchical clustering analysis, and the ellipses present an 80% confidence interval,
assuming normal distribution. For visualization purposes, this plot is a section focussing on the categorical and continuous variables contributing
to the ordination. The full size version of the CCpnA triplot, including all samples and OTUs, is presented in Figure S2A. Abbreviations of variables
are the same as in Fig. 2
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Fig. 5 Bacterial community state types over time in patients undergoing allogeneic HSCT. Patients are grouped into four outcome groups: (1)
patients who developed no or mild aGvHD (grade 0–I) and survived vs. (2) patients who did not survive; (3) patients who developed moderate to
severe aGvHD (grade II–IV) and survived vs. (4) patients who did not survive. The day of commencement of aGVHD grade II–IV and the day of
death post-HSCT are displayed to the right. Patients with moderate to severe aGvHD (groups 3 and 4) most often harbored the Lactobacillaceae-
dominated community state type 1 (CST 1), especially at late time points. CST2, dominated by Ruminococcaceae and Lachnospiraceae, did not
persist after HSCT in any of the patients in groups 3 and 4. A detailed overview of the CSTs is provided in Additional file 7: Figure S4, and
information about individual OTUs and their cluster-affiliation is provided in Additional file 5: Table S3
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Fig. 6 Longitudinal profiles of microbial community composition and immune markers in non-survivors with aGvHD. Abundances of
Lactobacillaceae increased predominantly after aGvHD onset in patients who died during the follow-up period. Patient P24 developed chronic
GvHD on day + 187, relapsed on day + 548, and died on day + 784 due to graft rejection after re-transplantation. Patient P26 died on day + 602
after a relapse on day + 442 followed by re-transplantation on day + 518. Patient P30 died on day + 192 after relapse on day + 77. Patient P26
and P30 had no reported bacterial infections during the depicted period. InvSimpson inverse Simpson diversity index, hBD2 human beta-defensin
2, aGvHD acute graft-versus-host-disease, inf bacterial infection
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point (1×: n = 6, 2×: n = 3, 3×: n = 1) (Fig. 5). Half of
the patients (four out of eight) with moderate or severe
aGvHD were also assigned to CST 2 once, but only at
the time point before transplantation (Fig. 5). That is, a
Ruminococcaceae- and Lachnospiraceae-dominated com-
munity only persisted in patients with no or mild
aGvHD.
Persistence of Enterococcaceae-dominated community
state type
A subcluster of cluster 2 comprised two facultative anaer-
obe Enterococcus spp. (GQ1330038.1 and AJ272200.1),
exhibiting positive correlations with high NK and B cell
counts (Fig. 3b) and contributing to the separation of the
clusters (Fig. 3c). Enterococcaceae was the most abundant
family in the overall study population (Fig. 1d), and com-
munity state typing revealed a state type predominantly
characterized by Enterococcaceae (CST 4, Additional file
8: Figure S5). A total of nine out of 22 patients (41%) with
no or mild aGvHD were assigned to CST 4 at least at one
time point (1×: n = 2, 2x: n = 2, ≥ 3×: n = 5) and this
Enterococcaceae-dominated CST often persisted in the pa-
tient over time (Fig. 5). A quarter of the patients (two out
of eight, both survivors) with moderate or severe aGvHD
were assigned to CST 4 at least at one time point on the
day of or post-HSCT (Fig. 5).
High inflammation in patients with high facultative
anaerobic bacteria
In multivariate analyses, OTUs belonging to facultative an-
aerobic Enterobacteriaceae and Staphylococcaceae were
characteristic for sPLS cluster 3 (Fig. 3a, b, Additional file 5:
Table S3). Cluster 3 was further comprised of high plasma
citrulline concentrations pre-HSCT (before conditioning)
and week + 1, high monocyte counts in week + 3, high
CD4+ T cell counts in month + 2, high CRP levels, particu-
larly in weeks + 1, + 5, and + 6 (Fig. 3a, b). The projection
of the variables in the sPLS suggested a weak positive cor-
relation between these clinical variables in dimension 1
(Fig. 3a). However, a weak negative association between
CRP levels and monocytes (week + 3) as well as citrulline
and CD4+ T cell counts is indicated in dimension 2 (Fig.
3a), which is in agreement with some results of the Spear-
man’s rank correlation tests (Fig. 2).
The clinical variables in cluster 3, in particular high CRP
levels post-HSCT, exhibited positive correlations with the
OTUs predominantly affiliated with Proteobacteria (e.g.,
Enterobacteriaceae), Bacteroidetes, and Staphylococcus spp.
(Fig. 3b, Additional file 5: Table S3). The strongest positive
correlations occurred with several facultative anaerobe bac-
teria, e.g., Enterobacter sp. LCR81 (FJ976590.1), Escherichia
coli (FJ950694.1), and Staphylococcus sp. (JF109069.1). The
CCpnA supported observations from the sPLS regression
regarding cluster 3, but indicated that they were only
represented by a few patient samples (Fig. 4 and Additional
file 6: Figure S3A). These samples were characterized by
high CRP levels, especially in week + 1, + 5, and + 6. High
CRP levels at these time points were not associated with
aGvHD grade, i.e., they were not higher in patients with ei-
ther aGvHD grade 0–I, or grade II–IV. OTUs of cluster 3,
i.e., members of Enterobacteriaceae and Staphylococcaceae,
exhibited their highest abundances in samples of this clus-
ter (Fig. 4 and Additional file 6: Figure S3A). Of note, pa-
tients represented in cluster 3 were younger compared to
those in the other two clusters (Fig. 4).
Discussion
The human immune system and host-associated microor-
ganisms are closely interlinked and play central roles in
health and disease. The underlying components and mech-
anisms facilitating interactions between the immune system
and microorganisms are however not completely under-
stood. Understanding these associations is particularly rele-
vant in patients that receive components of a “foreign”
immune system, such as in patients undergoing allogeneic
HSCT. Because both the patients’ immune system and
microbiome appears severely affected, they potentially
jointly impact on clinical outcomes. Here, we perform an
integrated analysis of immune markers, immune reconstitu-
tion data, clinical outcomes, and microbiota, and we pro-
vide evidence for the association between specific microbial
taxa, host immune markers, immune cells, and clinical
outcomes.
We observed that a predominance of Clostridiales, rep-
resented by Ruminococcaceae and Lachnospiraceae, in the
intestine did not persist after transplantation in patients
who either developed aGvHD grade II–IV, died, or both.
Clostridiales are common colonizers of the healthy distal
gut [23], and their loss is associated with microbial com-
munity disruption, reduced diversity, and GvHD [14]. A
low diversity before conditioning and at the time of en-
graftment is associated with increased mortality [4, 5], in
line with our findings.
In addition, in our multivariate analyses, we observed
high plasma hBD2 levels before HSCT and in weeks + 1
and + 2 post-HSCT in patients who developed aGvHD
grade II–IV, died, or both. The reason for the high hBD2
levels before HSCT in patients with increased mortality
and GvHD is unknown at present. One could speculate
that it relates to a higher burden of inflammation before
and during the first 2 weeks post-transplantation. This
was also reflected in higher counts of (recipient-derived)
monocytes pre-HSCT that, by secreting hBD2, might con-
tribute to an inflammatory reaction and thereby a poten-
tially higher risk of aGvHD after HSCT. However, hBD2
concentrations did not correlate with CRP levels in any of
our multivariate analyses, and accordingly our data do not
support a clear association between levels of systemic
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inflammation and high hBD2 levels. High hBD2 concen-
trations in weeks + 1 and + 2 could be an indicator for an
innate immune reaction involving donor-derived cells, for
example, against opportunistic pathogens that may have
translocated to the bloodstream [24]. This might have
been promoted by the decrease in Ruminococcaceae and
Lachnospiraceae abundances in these patients after HSCT,
indicating a microbial community disruption. Plasma
hBD2 concentrations were characterized for the first time
here in HSCT patients, and our findings emphasize the
importance for further investigations to exploit the poten-
tial of hBD2 as a novel candidate marker for outcomes
after HSCT. Importantly, our data suggested that differ-
ences in hBD2 secretion levels between patients were
highly dependent on both, the microbial community com-
position and the time point relative to HSCT. We suggest
that further investigations take into account variations of
microbial community patterns and temporal changes
when assessing hBD2 in the HSCT context. Moreover,
these findings may be refined with a sampling time point
homogeneity that is higher than what we provide in this
study.
An interesting observation was that high pre-HSCT hBD2
levels and monocyte counts were associated with high abun-
dance of Lactobacillaceae independent of time point. Pro-
biotic Lactobacillus spp. have previously been shown to
enhance hBD2-secretion in immune cells, thereby contribut-
ing to the innate immune defense [25, 26]. This mechanism
could play a protective role during blood stream infections
by opportunistic pathogens in HSCT patients. The increase
of Lactobacillaceae abundances, particularly after the onset
of aGvHD in patients who died, may be explained by a pre-
viously proposed compensatory mechanism to reduce
aGvHD severity after onset in mice and humans [14]. For
instance, high abundances of Lactobacillaceae could indicate
homeostasis in the gut microbiome of children and thereby
prevent inflammation caused by opportunistic pathogen ex-
pansion [27, 28]. Reduced intestinal inflammation might
then benefit the outcome of aGvHD. This might however
also lead to a less effective graft-versus-leukemia (GvL) effect
as suggested by the finding that all patients, for which we
observed moderate to severe aGvHD and subsequent in-
creased Lactobacillaceae post-HSCT, overcame aGvHD, but
died following a relapse. Only a few patients in our study
represented this combination of outcomes (moderate to se-
vere aGvHD with subsequent increase of Lactobacillaceae
and death), therefore no significant conclusion can be drawn
at this point and further studies are needed to address these
observations in more detail.
We provide a discussion on survival following high Lac-
tobacillaceae abundances prior to the onset of aGvHD in
Additional file 10.
In contrast to patients with moderate to severe
aGvHD, we observed a higher overall survival in patients
with no or mild aGvHD in multivariate analyses. The lat-
ter patients also had increased numbers of NK and B cells.
In agreement with our study, previous studies have shown
slower NK cell reconstitution after HSCT in patients with
moderate to severe aGvHD compared to those with no or
mild aGvHD [29]. Moreover, our results are in agreement
with the previously described association of low NK cell
numbers after HSCT and reduced overall survival [30], in
line with NK cells’ crucial role in the GvL effect [7]. A
poor recovery of B cells has been found to pose an in-
creased risk of late infections [31], which might be an ex-
planation for the association of high B cell counts and
lower survival. The lower B cell numbers we observed in
patients with more severe aGvHD could partially be a
consequence of aGvHD or the treatment with corticoste-
roids, which is known to reduce the number of B cell pre-
cursors [21, 29]. However, due to the design of this study,
we are not able to differentiate between the roles of these
two potential causes that may also act in synergy. How-
ever, based on our findings, the intestinal microbiota
could also play a contributing role, because faster NK and
B cell reconstitution as well as lower aGvHD severity, and
higher overall survival were associated with high abun-
dances of obligate anaerobes belonging to Ruminococca-
ceae and Lachnospiraceae. Indeed, decreased abundances
of these bacterial families have previously been associated
with an overall microbial disruption and decreased diver-
sity [5, 15, 32]. In line with our observations, reduced mi-
crobial diversity was shown to contribute to lower survival
[4] and a reduction of Clostridiales was observed in pa-
tients presenting aGvHD [14]. Furthermore, in melanoma
patients, a low diversity and decreased Ruminococcaceae
abundance were associated with a poor response to im-
munotherapy [33]. A potential explanation for this associ-
ation could be that members of the order Clostridiales can
downregulate inflammation and might thereby prevent
aGvHD. Anti-inflammatory components produced by
Clostridiales include, for example, urinary 3-indoxyl sul-
fate (3-IS) [34] and butyrate [35]. Acute GvHD might also
reinforce microbial community disruption, as it is known
to be accompanied by a reduction of Paneth cell numbers
in the intestine. Paneth cells are secretors of α-defensins,
important modulators of gut microbial homeostasis [36].
In contrast to the patient group with high abundances
of obligate anaerobic bacteria (e.g., Ruminococcaceae
and Lachnospiraceae), patients with high abundances of
facultative anaerobic bacteria (e.g., Enterobacteriaceae,
Staphylococcus spp., and Streptococcus spp.) showed slow
NK and B cell reconstitution. An increase in facultative
anaerobic bacteria has previously been observed in the gut
microbiome of HSCT recipients before the start of condi-
tioning compared with donors [5]. Here, we additionally
observed high levels of C-reactive protein (CRP), indicat-
ing high inflammation in these patients. This would be in
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line with the notion that systemic inflammation during
the phase of gastrointestinal toxicity after chemotherapy is
partially caused by pathogen associated molecular patters
(PAMPs) released by translocating bacteria, inducing the
release of inflammatory cytokines through binding to Toll
like receptors expressed by immune cells, epithelial cells,
and other tissue cells. However, the design of the current
study does not allow drawing conclusions regarding caus-
ality here. Another possible explanation for this associ-
ation might involve the shift to microbial growth
conditions that favor facultative anaerobic bacteria during
intestinal inflammation, such as an increased availability
of oxygen caused by inflammatory products [37]. Our
multivariate analyses indicated that the patients in which
we observed these associations were younger compared to
the rest of the cohort. Therefore, one could speculate that
an immature intestinal microbiome might exhibit a higher
susceptibility to opportunistic growth of facultative anaer-
obic bacteria. Further investigations will have to elucidate
this relation and its potential consequences for adjust-
ments of monitoring and treatment by age.
We provide a discussion on our findings regarding as-
sociations of adverse outcomes with Enterococcus com-
pared with previous studies in Additional file 10.
Antimicrobial treatment of patients can significantly
affect the gut microbiota, especially in children [38].
Early use of antibiotics in general has been found to re-
duce Clostridiales in the intestine of HSCT patients [39].
Furthermore, a link of high total amounts of antibiotic
in GvHD development has been observed in pediatric
stem cell recipients [40]. However, to our knowledge,
the effects of specific antibiotics on the intestinal micro-
biome especially in pediatric HSCT patients have not yet
been elucidated in detail. Here, we identified a number of
specific antibiotics, including vancomycin and ciprofloxacin,
associated with simultaneous reduction of Clostridiales (in
particular Ruminococcaceae and Lachnospiraceae), similar
to what has previously been observed in adult patients [41].
Most interestingly, we found that treatment with vanco-
mycin and ciprofloxacin was not only associated with re-
duced Clostridiales, but also with increased abundances of
facultative anaerobic bacteria, e.g., Enterobacteriaceae
(gamma-Proteobacteria). In this patient cohort, these anti-
biotics were generally given intravenously. Oral vanco-
mycin-treatment in a cohort of rheumatoid arthritis
patients was previously shown to be associated with an ex-
pansion of Proteobacteria [42]. The use of a prophylactic
ciprofloxacin treatment to prevent chemotherapy- and
transplantation-related bloodstream infections is an estab-
lished method [43], and it was proposed that fluoroquino-
lones (the antibiotic class comprising ciprofloxacin) can
prevent intestinal domination of Proteobacteria in HSCT
patients [15]. However, ciprofloxacin treatment in healthy
subjects has been associated with decreased microbial
diversity and decreased Ruminococcaceae and Lachnospira-
ceae abundances [44], indicating microbial community dis-
ruption. Therefore, our findings further challenge the
choice of antibiotics, such as vancomycin and ciprofloxacin,
in patients undergoing chemotherapy and HSCT. Interest-
ingly, in the present study, a number of less frequently used
antibiotic agents, e.g., ceftazidime (a cephalosporin), showed
positive associations with high Clostridiales abundances. In
agreement, another cephalosporin (cefepime) has previ-
ously been attributed clostridial sparing effects [45]. How-
ever, ceftazidime was associated with reduced bacterial
alpha diversity to a similar degree as vancomycin and cipro-
floxacin in a previous study [41]. Elucidating the effects of
antibiotic agents potentially contributing to maintaining gut
microbial homeostasis in HSCT therefore require further
investigation. Of note, we did not take the mode of applica-
tion of the antibiotics into account here, which might limit
the strength of our conclusion since, e.g., an effect of vanco-
mycin on the microbiota might be greater when applied
orally compared to intravenously. It remains to be deter-
mined whether certain antibiotics modulate the patients’
microbiome and how this might lead to either positive or
adverse clinical outcomes.
Conclusions
Our findings support the increasing evidence of micro-
bial involvement in the context of HSCT in cancer pa-
tients. We provide evidence for the association between
specific microbial taxa and host immune markers. In
particular, we examined the prognostic potential of im-
mune markers and gut microbial community dynamics for
immune reconstitution and outcomes after HSCT by re-
vealing multivariate associations. We observed increased
human beta-defensin 2 in patients with moderate to severe
aGvHD and high mortality. In those patients, NK and B cell
reconstitution was slow compared to patients with low
mortality. These associations only applied when distinct gut
microbial abundance patterns were observed, namely low
abundances of Ruminococcaceae and high abundances of
Lactobacillaceae. Therefore, hBD2, in connection with lon-
gitudinal microbial community pattern surveillance, could
be further evaluated as a potential novel candidate marker
to identify patients at risk of adverse outcomes (e.g.,
aGvHD) and slow immune cell reconstitution after HSCT,
contributing to improved clinical outcomes. Of note, our
cohort comprised a relatively small number of patients with
different primary diseases and conditioning regimens, and
our findings would therefore benefit from being assessed in
larger, more homogenous patient groups. Importantly, mi-
crobial abundances also depended on antibiotic treatment.
Our findings suggest that certain antimicrobial agents
might contribute to a shift from obligate to facultative
anaerobes. This highlights the need to assess the usage of
specific antibiotics in more detail and to take antibiotic
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treatment into consideration when describing microbial
communities in HSCT recipients.
Methods
Patient recruitment and sample collection
We recruited 37 children (age range 1.1–18.0 years) under-
going their first myeloablative allogeneic hematopoietic stem
cell transplantation at Copenhagen University Hospital Rig-
shospitalet, Denmark, from June 2010 to September 2012.
Patients’ clinical characteristics are listed in Additional file 1:
Table S1. Further information can also be found in previous
studies where the cohort has been examined in relation to
other questions [17, 46–48]. All patients received pretreat-
ment with a myeloablative conditioning regimen, starting on
day − 7 (Additional file 1: Table S1). Four patients were re-
transplanted at day + 157, + 518, + 712, and + 1360 after the
first transplantation, respectively.
Sampling time points were defined according to the fol-
lowing intervals: pre-HSCT (collected between day − 33
and day − 3), at the time of HSCT, preferably before graft
infusion (collected between day − 2 and day + 2) and
weekly during the first 6 weeks after transplantation (week
+ 1: day + 3 to day + 10, week + 2: day + 11 to day + 17,
week + 3: day + 18 to day + 24, week + 4: day + 25 to day
+ 31, week + 5: day + 32 to day + 38, week + 6: day + 39 to
day + 45) (Fig. 1a). Broader intervals applied to follow-up
time points: month + 1 (between days + 21 and + 44),
month + 2 (between days + 45 and + 70), month + 3 (be-
tween days + 77 and + 105), month + 6 (between days +
161 and + 197), and 1-year post-transplantation (between
days + 346 and + 375).
Infections and antibiotics
Bacterial infections from before transplantation until 1 year
post-HSCT were taken into consideration for downstream
analysis. For each time point, it was recorded whether any
bacterial infection occurred within the respective specified
interval or not (1/0). Antibiotic treatment from before
HSCT (from day − 90) until month + 2 was taken into
consideration. We included only those time points corre-
sponding to the time points of microbiota profiling into
downstream analyses.
Analysis of T, B, and NK cells in peripheral blood
T, B, and NK cell counts were determined in months + 1, +
2, + 3, and + 6 post-transplantation. Lymphocyte subsets in
peripheral blood were quantified using Trucount Tubes
(Becton Dickinson, Albertslund, Denmark) together with
the following panel of conjugated monoclonal antibodies
and analyzed on a FC500 flow cytometer (Beckman Coulter,
Copenhagen, Denmark): CD3-PerCP, CD3-FITC, CD4-
FITC, CD8-PE, CD45-PerCP, CD16/56-PE, CD20-FITC,
and CD19-PE (Becton Dickinson). CD3+ T cells, CD3+CD4+
T cells, and CD3+CD8+ T cells were determined. NK cells
were differentiated by CD3−CD45+CD16+CD56+ phenotype.
The following B cell phenotypes were distinguished: total B
cells (CD45+CD19+), mature B cells (CD45+CD19+CD20+),
and immature B cells (CD45+CD19+CD20−). Data of these
immune cell populations have been published previously in
a different context [46].
Analysis of monocytes and neutrophils
Leukocyte numbers and subsets were monitored daily
during hospitalization and subsequently every week in
the outpatient clinic using flow cytometry (Sysmex XN)
or, in case of very low leucocytes, counted by micros-
copy (CellaVision DM96 microscope). Mean monocyte
and neutrophil counts were calculated for further ana-
lysis per time point according to the intervals specified
above.
Quantification of inflammatory markers
EDTA-anticoagulated and heparinized blood was sam-
pled and then centrifuged within 2 h after collection.
The plasma was isolated and cryopreserved in 0.5-ml ali-
quots at − 80 °C. IL-6 levels on day + 7 were determined
in EDTA-anticoagulated plasma using the Human Th1/
Th2/Th17 Cytometric Bead Array kit (Becton, Dickinson
and Co., Denmark) and a FACSCalibur flowcytometer
(Becton, Dickinson and Co), according to the manufac-
turer’s instructions with a detection limit of 2.5 pg/ml.
IL-6 data have been published previously in another
context for a larger cohort than the patients included
here [17, 47]. CRP levels were measured daily by Modu-
lar P Modular (normal range, 0 to 10 mg/L) at the De-
partment of Clinical Biochemistry, Copenhagen
University Hospital Rigshospitalet, Denmark. Mean CRP
levels were calculated for further analysis per time point
according to the intervals specified above. Mean CRP
levels pre-HSCT include measurements from day − 7 to
day − 3, i.e., the days after the start of conditioning (ex-
cept for day − 7).
Quantification of citrulline
Plasma citrulline concentrations pre-HSCT (before the
start of conditioning (day − 7)) and at days + 7 and + 21
were measured by reverse-phase high-performance liquid
chromatography of their phenylisothiocyanate derivatives
from heparinized plasma, as described previously [17, 47].
Citrulline levels have previously been described for pa-
tients of this cohort in a different context [17, 47].
Enzyme-linked immunosorbent assay of human beta
defensins
Human beta defensin 2 and 3 (hBD2 and hBD3) concentra-
tions in heparinized plasma samples of 37 patients at eight
time points (pre-HSCT (before start of conditioning, except
for four patients sampled at day − 6 or − 5), on the day of
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transplantation, weeks + 1 to + 4, month + 2 and + 3) and
ten healthy controls (sampled once each) were quantified
by two-step sandwich enzyme-linked immunosorbent assay
(ELISA) following the manufacturer’s instructions (Pepro-
tech Human BD-2 and BD-3, Standard ABTS ELISA
Development Kit, cat.no. 900-K172 and 900-K210, respect-
ively). The healthy control group comprised ten young
adults (four males, six females) with an average age of 22
(range 19–24 years). Samples of three out of ten healthy in-
dividuals were additionally spiked to a peptide concentra-
tion of 1000 pg/ml. Two replicates were measured per
sample and their mean was used for further analysis. Sam-
ples were measured undiluted as well as in 1:4 and 1:16 di-
lutions to also cover concentrations potentially exceeding
the upper detection limit. Samples with very high concen-
trations were additionally measured in 1:32 and 1:128 dilu-
tions. Detection limits were 16–2000 pg/ml for hBD2 and
31–4000 pg/ml for hBD3. Absorbance was measured on a
VICTOR™ X3 Multilabel Plate Reader (Perkin Elmer, Inc.,
USA) at 405 nm. Wavelength correction at 540 nm was
used to prevent optical interference caused by the material
of the microtiter plate. Concentrations of hBD3 were
mostly below the limit of detection, except for a few excep-
tionally high measurements (average 1450.69 pg/ml, me-
dian 0 pg/ml, range 0–279038.71 pg/ml).
DNA isolation from fecal samples and 16S rRNA gene
sequencing
Fecal samples for analysis of the intestinal microbiome
were collected from a subset of 30 patients at seven time
points: pre-HSCT (five patients were sampled after the
start of conditioning (between day − 6 and day − 4)), at
the time of HSCT and once weekly during the first five
weeks after transplantation. The intestinal microbiome
was characterized at 1–2 time points in eight patients
(27%), at 3–4 time points in 15 patients (50%), and at 5–
6 time points in eight patients (27%) (Additional file 1:
Table S1). In patients who underwent re-transplantation,
no feces samples collected after the second transplant-
ation were included in this study. In total, 97 fecal sam-
ples were obtained.
DNA from fecal samples and a blank control were iso-
lated with the use of the Maxwell 16 Instrument (Promega
Corporation) following the manufacturer’s instructions for
the low elution volume blood DNA system. Alterations to
the protocol included additional lysozyme treatment and
bead beating with stainless steel beads for 2 min/20 Hz in a
tissue lyser (Qiagen). In each sample including the blank
control, the V4–V5 region of the 16S ribosomal RNA gene
were amplified in PCR using the following barcoded
primers: 519F (5#-CAGCAGCCGCGGTAATAC-3#) and
926R (5#-CCGTCAATTCCTTTGAGTTT-3#). Amplicons
were then analyzed for quantity and quality in an Agilent
2100 Bioanalyzer (Agilent Technologies) with the use of an
Agilent RNA 1000 Nano Kit. For library preparation, 50 ng
of DNA from each sample was pooled with multiplex iden-
tifiers for 2-region 454 sequencing on GS FLX Titanium
PicoTiterPlates (70675) with the use of a GS FLX Titanium
Sequencing Kit XLR70 (Roche Diagnostics). Library con-
struction and 454 pyrosequencing were performed at the
National High-Throughput DNA Sequencing Center, Uni-
versity of Copenhagen.
16S rRNA gene sequence pre-processing
Raw 454 sequence reads stored in standard flowgram
format (SFF) were extracted, converted to and stored in
FASTA format with associated quality files (containing
sequence quality scores) using the sffinfo command of
the bioinformatics software tool mothur [49]. Trimming
according to the clipQualLeft and clipQualRight values
provided by the sequence provider was disabled because
cut-off values are opaque and not customizable.
Analysis was continued in the Quantitative Insights Into
Microbial Ecology (QIIME; version 1.9.0) bioinformatics
pipeline [50]. FASTA files were demultiplexed and quality
filtered using the script split_libraries.py (Mapping files are
available from figshare (https://doi.org/10.6084/m9.figshare.
6508250)). As the samples were sequenced bidirectional,
each FASTA file was demultiplexed in two steps. Firstly,
based on a mapping file containing the 519F primer as the
“LinkerPrimerSequence” and the 926R primer as the
“ReversePrimer,” both in 5′ to 3′ orientation. Secondly,
based on a mapping file containing the 926R primer as the
“LinkerPrimerSequence” and the 519F primer as the
“ReversePrimer,” again both in 5′ to 3′ orientation.
Reads between 200 and 1000 bp length and a minimum
quality score of 25 were retained (default). Sequences with
homopolymers longer than 200 bp were removed from
the data set. Removal of reverse primer sequences (-z
truncate_only option) was disabled during demultiplexing.
Subsequently, the demultiplexed FASTA files that were
not yet primer-truncated were then used to denoise flow-
grams (.sff.txt files also generated by mothur’s sffinfo) with
QIIME’s denoise_wrapper.py script. Reverse primer-trun-
cation had not been done yet to ensure compatibility be-
tween FASTA and .sff.txt files. The denoised FASTA
output files were then inflated, i.e., flowgram similarity be-
tween cluster centroids was translated to sequence simi-
larity, to be used for OTU picking. Reverse primers and
subsequent sequences in the demultiplexed and denoised
FASTA files were then truncated using the truncate_re-
verse_primer.py script. In the following step, the orienta-
tion of the primer-truncated reads that started with the
926R primer as the “LinkerPrimerSequence” was adjusted
by reverse complementation (with the script adjust_seq_
orientation.py). All trimmed reads were then concatenated
to a single file for further analysis.
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Chimeras were identified using the script identify_
chimeric_seqs.py and method usearch61, which performs
both de novo (abundance-based) and reference-based detec-
tion (by comparing the dataset to the chimera-free reference
database Ribosomal Database Project (RDP; training data-
base version 15)). Only those sequences that were flagged as
non-chimeras from both detection methods were retained
(option –non_chimeras_retention = intersection). Oper-
ational taxonomic unit (OTU) clustering was performed,
using the script pick_otus.py (based on the SILVA database,
Silva_119_rep_set97). OTU tables in BIOM format were
created with make_otu_table.py (and subsequently con-
verted to JSON BIOM format to be compatible with analysis
in R [51] with the package phyloseq [52]). The OTU table
and the taxonomy table are available from figshare (https://
doi.org/10.6084/m9.figshare.6508187).
Statistical analyses
Statistical analyses and creation of graphs were performed
with the program R (Version 3.4.0, R Foundation for Statis-
tical Computing, Vienna, Austria) [51]. All R scripts docu-
menting our statistical analyses are available from figshare
(https://doi.org/10.6084/m9.figshare.6508238). Sequencing
data and all related experimental and clinical data (data sets
available from figshare, https://doi.org/10.6084/m9.figshare.
6508232) were integrated for analysis with the R package
phyloseq and its dependencies [52] (Additional file 11). The
resulting phyloseq objects are provided through figshare
(https://doi.org/10.6084/m9.figshare.6508235). Plots were
generated with the packages ggplot2 [53], plotly [54], and
mixOmics [55]. Dose-response analysis of the ELISA data
was performed with four-parameter log-logistic models in
the R package drc [56].
Alpha diversity (measured by inverse Simpson index),
levels of human beta-defensin 2 (hBD2) concentration, citrul-
line and C-reactive protein (CRP), as well as monocyte
counts, NK cell counts, total B cell counts, and CD4+ T cell
counts at different time points were compared using Fried-
man tests with Benjamini-Hochberg correction for multiple
testing (Additional files 3: Figure S2, Additional files 11 and
12). In addition, Kendall’s coefficient of concordance (Ken-
dall’s W) was calculated on ranked data for each marker
(Additional file 13). Like the Friedman test, the test for Ken-
dall’s W allowed the comparison of marker levels between
time points. In addition, the coefficient of concordance in-
forms about the level of agreement between patients. There-
fore, Kendall’s W can be interpreted as a measure of effect
size for the Friedman tests. A Kendall’s W < 0.1 was consid-
ered as indicating a small effect, 0.1–0.5 as a moderate effect,
and > 0.5 as a strong effect. As an exception, hBD2 in healthy
controls was compared with hBD2 in patients at individual
time points by using Wilcoxon rank-sum tests, because
hBD2 was only measured once in the healthy control individ-
uals and can therefore not be analyzed in a Friedman test
designed for repeated measurements. Monocyte counts in
Additional file 2: Figure S1B are depicted at more time points
than indicated in Fig. 1a because not all time points were in-
cluded into further analyses. The day of HSCT, week + 1,
and week + 2 were excluded as data were missing for ≥ 40%
of the patients. Months + 2, + 3, and + 6, as well as 1 year
were chosen as representative follow-up time points for fur-
ther analyses as indicated in Fig. 1a.
A core set of OTUs was obtained by retaining 256 OTUs
(out of 756 OTUs) with ≥ 5 reads in ≥ 2 samples using the
function kOverA() from R package genefilter [57]. Subse-
quently, 17 OTUs that were more abundant in the blank
control than in the majority of samples were removed as
potential contaminants prior to downstream analyses. The
resulting count data set of 239 OTUs was transformed for
subsequent analyses using the function varianceStabilizing-
Transformation() in the package DESeq2 [58] (Additional
file 11). The function implements a Gamma-Poisson mix-
ture model [59] to account for both library size differences
and biological variability.
Median imputations were performed for continuous
clinical and immune marker data with less than 20%
missing values. Variables with more than 20% missing
values were excluded from the analysis (Additional files
13 and 14). Central tendencies of immune cell counts at
single time points in relation to clinical outcomes (max-
imum aGvHD grade 0–I vs. grade II–IV) were assessed
in univariate analyses by Wilcoxon rank-sum tests and
displayed in boxplots (Additional file 14).
A model selection procedure was implemented to find
the relevant variables to be included in subsequent multi-
variate analyses of how microbiome patterns are associated
with clinical outcomes, baseline parameters, and immune
parameters during the course of transplantation: a Manhat-
tan distance matrix of the variance-stabilized bacterial com-
munity data was calculated using the distance() function in
phyloseq [52]. Subsequently, permutational multivariate
analysis of variance using distance matrices (adonis) for
model selection was performed by applying the adonis2()
function in the package vegan [60] (Additional file 3: Figure
S2, Additional file 15). Permutation design was set up with
respect to repeated measurements within the same patients
and the intact chronological order of time points. Besides
immune marker levels and immune cell counts (pre- and
post-HSCT, i.e., recipient- and donor-derived cells, respect-
ively) at the time points described above, we included clin-
ical outcomes (i.e., overall survival, aGvHD (grade 0–I vs.
II–IV), and relapse) after transplantations, antibiotic treat-
ment during the course of transplantation, and clinical
patient characteristics in the model to account for possible
effects of recipient age at the time of transplantation, recipi-
ent sex, donor type (sibling vs. unrelated), malignant vs. be-
nign diagnosis, graft type (stem cell source: bone marrow,
umbilical cord blood, or peripheral blood), and application
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of irradiation therapy (yes/no). Variables that were found to
be significant (P ≤ 0.05) in the adonis analysis were in-
cluded in subsequent multivariate multi-table analyses, i.e.,
sparse partial least squares (sPLS) regression and canonical
correspondence analysis (CCpnA) (Additional file 15).
Choosing variables with significant effects in adonis for fol-
low-up statistical testing has been performed previously
[61]. Even though validation of the set of selected variables
through a data-splitting approach might be preferable, this
was not feasible due to our relatively small data set. To ac-
count for this and to avoid post-selective inference, we re-
nounce calculation of p values from the two analyses that
directly depend on the pre-selection (sPLS and CCpnA).
Correlations among the selected clinical variables were
assessed in correlation matrices based on Spearman’s
rank correlation tests (Additional file 3: Figure S2, Add-
itional file 14). Matrices were calculated using the rcorr()
function of the R package Hmisc [62] and displayed with
the package corrplot [63]. P values were calculated with
the rcorr.adjust() function with correction for multiple
testing (method “Holm”). The Spearman’s rank correl-
ation tests were performed on the set of variables se-
lected from the adonis analysis. However, here we assess
correlations among those variables, and not between
variables and microbial abundances.
Sparse PLS regression was performed by applying the
spls() function in the package mixOmics [55] (Additional
file 3: Figure S2, Additional file 15). The sPLS regression al-
lows the integration of the microbial community data
matrix and the clinical variable matrix for multiple regres-
sion. It is robust enough to handle collinearity and noise in
the data and is suitable to model multiple response vari-
ables [64]. The number of clinical variables to be kept in
the model for each component (keepY) was set to 23, corre-
sponding to the number of variables pre-selected with ado-
nis. We ran the sPLS regression with a range of numbers
(20–40) of OTUs to be kept for each component (keepX).
As the results were robust to this choice, keepX was set to
30. The number of components to choose was estimated
with the perf() function and set to ncomp = 2. The sPLS
model was run in regression mode. Thereafter, hierarchical
clustering was performed within the mixOmics cim() func-
tion based on the sPLS regression model with the clustering
method “complete linkage” and the distance method “Pear-
son’s correlation.” Coefficients of pairwise correlations be-
tween OTU abundances and clinical variables were thereby
obtained. Furthermore, loading plots were generated with
the function plotLoadings() (method = “mean”) to visualize
loading vectors of specific OTUs that contribute most to
the separation of variables in components 1 and 2.
Canonical (i.e., bidirectional) correspondence analysis
(CCpnA), a multivariate constrained ordination method,
was performed by using the cca() function in the package
vegan [60] (Additional file 3: Figure S2, Additional file 15).
In this method, the microbial community data matrix is
Chi-square transformed and weighted linear regression on
pre-selected constraining variables is performed. The
resulting fitted values are used for correspondence analysis
by singular value decomposition. CCpnA is a constrained
method in the sense that it does not aim at depicting all
variation in the data, but only the variation directly ex-
plained by the constraints (i.e., the provided set of pre-se-
lected variables). The resulting triplot is not displayed as a
square representation, but rather corresponds to the per-
centage of variance explained by axis 1 and 2, respectively,
as previously suggested [65]. In contrast to the sPLS analysis,
the CCpnA was performed in canonical mode, i.e., modeling
bidirectional relations between OTU abundances and clin-
ical variables. OTUs with a correlation of > 0.2/< − 0.2 in
the sPLS analysis were included in the CCpnA model.
As another approach to distinguish between microbial
community states of the intestinal microbiome, we
assigned samples to community state types (CSTs) by par-
titioning around medoid (PAM) clustering (function
pam() in package cluster [66]) based on a Jensen-Shannon
distance of the variance stabilized microbial count data (R
code modified after [67]) (Additional file 3: Figure S2,
Additional file 16). The number of clusters was deter-
mined by gap statistic evaluation and silhouette width
quality validation. We further assessed patients’ transitions
between CSTs over time. OTUs were assigned to CST-
based clusters (Additional file 4: Table S2) based on in
which CST they exhibited the highest average abundance
over all samples (within each CST). Furthermore, we
showed detailed longitudinal profiles of the microbial
community on family-level, and selected immune markers
for individual patients with aGvHD (Additional file 17).
Additional files
Additional file 1: Table S1. Clinical patient characteristics. General
patient characteristics, conditioning regimens, complications, and
outcomes for the pediatric cohort (n = 37) and the subcohort (n = 30)
for which the intestinal microbiome was characterized. Abbreviations:
HLA, human leukocyte antigen; TBI, total body irradiation; CY,
Cyclophosphamide; VP16, Etoposide; BU, Busulfan; MEL, Melphalan; GvHD,
graft-versus-host disease. (PDF 379 kb)
Additional file 2: Figure S1. Temporal patterns of immune markers and
immune cells in HSCT patients. (A) C-reactive protein (CRP) and plasma
citrulline levels in HSCT patients (n = 37) over time. CRP levels were
significantly higher prior to HSCT and until week +2 compared to all
following time points, e.g. at the day of HSCT (median: 16.93 mg/L, range:
1.22 - 85.28 mg/L) compared to week +3 (median: 3.92 mg/L, range: 1.22
- 55.89 mg/L) (P < 0.001). Plasma citrulline levels were significantly lower
in week +1 compared to pre-HSCT (P < 0.001) and week +3 (P < 0.001).
(B) Immune cell counts in HSCT patients over time. Monocyte counts are
depicted at more time points than indicated in Figure 1a, because not all
time points were included into further analyses (see Methods). NK cell
counts were higher in months +2 to +6 compared to in month +1 (P <
0.001). B cell counts as well as CD4+ T cell counts increased steadily from
month +1 to month +6 (P < 0.001). Y -axes in all plots, except for
citrulline, were log10-transformed for better visualization. Zeros were
Ingham et al. Microbiome           (2019) 7:131 Page 18 of 22
replaced with 1 to avoid undefined values on the log-transformed axes.
Asterisks indicate whether the component at each respective time point
was significantly different from any of the other time points (showing the
maximum significance level). * P < 0.05, ** P < 0.01 and *** P < 0.001. (PDF
419 kb)
Additional file 3: Figure S2. Workflow of the statistical analysis approach.
The diagram displays the major steps of the statistical analyses and their
dependencies. Multivariate analyses (blue box) constitute the main
approach, especially the multi-table analyses and clustering analyses (green
box). To unravel the complexity of the multivariate analyses, these were
supplemented with univariate analyses (upper grey box). (PDF 911 kb)
Additional file 4: Table S2. Results of Permutational Multivariate
Analysis of Variance Using Distance Matrices (adonis). Adonis was
employed for model selection to identify relevant immune markers and
immune cell types to be included in downstream analyses (See Methods
for details). Significant variables (P<0.05) are marked in bold.
Abbreviations: hBD2_sim, plasma human beta-defensin 2 levels at time
points simultaneous to microbiome characterization; CRP_sim, C-reactive
protein levels at time points simultaneous to microbiome
characterization; Lymphocyte_count_sim, total lymphocyte counts at
time points simultaneous to microbiome characterization; pIL6, plasma
interleukin 6 concentration; Citr, plasma citrulline concentration; CD3+,
CD3+ T cell counts; CD4+, CD3+CD4+ T cell counts; CD8+, CD3+CD8+ T
cell counts; B, total B cell (CD45+CD19+) counts; mat_B, mature B cell
(CD45+CD19+CD20+) counts. immat_B, immature B cell
(CD45+CD19+CD20-) counts; NK, natural killer cell counts; mean_mono,
mean monocyte counts at indicated time point; mean_neutro, mean
neutrophil counts at indicated time point; Timepoints: pre, prior to
transplantation; w0, on the day of transplantation; w1, w2, w3, w4, w5:
one, two, three, four and five weeks after transplantation, respectively;
m1, m2, m3, m4, m6: one, two, three, four and six months after
transplantation, respectively; 1y, 1 year post-transplantation. (PDF 461 kb)
Additional file 5: Table S3. Taxonomy and cluster affiliation of OTUs
strongly associated with host-related variables based on sPLS analysis and
community state typing (CST). List of the 57 OTUs correlated strongest with
variables in the sPLS analysis (>0.2/<-0.2) . SPLS-based clusters were
determined by applying the mixOmics cim() function to the sPLS regression
model (hierarchical clustering method: complete linkage, distance method:
Pearson’s correlation) (see Methods). Four community state types (CSTs)
were defined by clustering of fecal samples with similar microbial
community compositions by partitioning around medoid (PAM) clustering
(see Methods). OTUs were then assigned to the CST-based clusters in which
they exhibited the highest average abundance over all samples. The same
taxonomic families dominated in sPLS- and CST-based clusters, respectively.
Cluster 1 was dominated by Lactobacillaceae. Cluster 2 was characterized
mainly by Ruminococcaceae and Lachnospiraceae. Cluster 3 harbored
Proteobacteria (P), e. g. Enterobacteriaceae. CS-typing revealed one
additional cluster (4), characterized by a high abundance of Enterococcaceae
and Staphylococcaceae. OTU numbers refer to the SILVA database
(silva_119_rep_set97). Phyla abbreviations: F, Firmicutes; B, Bacteroidetes; A,
Actinobacteria; P, Proteobacteria; FU, Fusobacteria. (PDF 505 kb)
Additional file 6: Figure S3. Canonical correspondence analysis
(CCpnA) of immune markers and intestinal bacterial taxa in patients
undergoing HSCT. Triplots showing dimension 1 and 2 of the CCpnA
that includes continuous clinical variables (arrows), categorical variables
(+), and OTUs (circles). Samples are depicted as triangles. OTUs with a
correlation of >0.2/<-0.2 in the sPLS analysis were included in the CCpnA
model. Only the variables and OTUs with a score >0.2/<-0.2 in at least
one CCpnA dimension are shown. The OTUs in the CCpnA plots are
colored according to the cluster they were affiliated with in the sPLS-
based hierarchical clustering analysis, and the ellipses present an 80%
confidence interval, assuming normal distribution. (A) Full size
visualization corresponding to the CCpnA model shown in Figure 4. Plot
dimensions correspond to the explained variances of each component.
(B) CCpnA including antibiotic treatment at time points simultaneous to
microbiome characterization. Antibiotics were added as categorical
variables. Depiction of the antibiotic’s name (in red) indicates
administration of the particular antibiotic, and the extension “_0”
indicates no administration of the respective antibiotic. Abbreviations of
variables are the same as in Figure 2. Further abbreviations: graft_BM: stem
cell source bone marrow; graft_UC: stem cell source umbilical cord blood.
(PDF 1356 kb)
Additional file 7: Figure S4. Clustered image map (CIM) of OTU
abundances by patient in the first two sPLS dimensions. Hierarchical
clustering of OTU abundances (bottom) and patients’ fecal samples (right)
(clustering method: complete linkage, distance method: Pearson’s
correlation) was performed within the mixOmics cim() function based on
the sPLS regression model. High abundance of an OTU in a sample is
represented as positive correlation in the map (red) and low abundance as
negative correlation (blue). The sampling time points of the fecal samples
are displayed in the side bar on the left (blue gradient from pre-HSCT time
point (light blue) to week +5 post-HSCT (dark blue)). The top side bar shows
taxonomic information on family level. Sample names on the right indicate
patient (P) and time point (pre: pre-HSCT, d0: day of HSCT, w: week). An “a”
or “b” indicates that two samples were collected from the respective patient
at the same time point, but on two different days. (PDF 491 kb)
Additional file 8: Figure S5. Community state types and gut microbial
patterns. Heat map of variance stabilized counts of the 50 most
abundant OTUs of the intestinal microbiome over all samples, grouped
into community state types (CSTs). Based on their OTU-composition,
samples were assigned to community state types (CSTs) by partitioning
around medoid (PAM) clustering using Bray-Curtis distance. The optimal
number of clusters (k = 4) was estimated from the gap statistic and
Silhouette width validation. Members of the Lactobacillaceae family
dominated the abundance profiles within CST 1. CST 2 exhibited
domination by Lachnospiraceae, Erysipelotrichaceae and Ruminococcaceae
members. Enterobacteriaceae, Streptococcaceae and Staphylococcacea
were characteristic for CST 3. CST 4 was characterized by a high
abundance of Enterococcaceae. Average Silhouette width was s(i) = 0.16
(range: -0.02 – 0.36), with CST 1 and CST 4 being the best defined
clusters (s(i) = 0.23 and 0.36, respectively). A Silhouette coefficient s(i)
close to 1 indicates appropriate clustering of the respective samples.
Sample names at the bottom indicate patient (P) and time point (pre:
pre-HSCT, d0: day of HSCT, w: week). An “a” or “b” indicates that two
samples were collected from the respective patient at the same time
point, but on two different days. (PDF 516 kb)
Additional file 9: Figure S6. Longitudinal profiles of microbial
community composition and immune markers in patients with aGvHD who
survived. In three representative patients with moderate to severe aGvHD
who survived, high abundance of Lactobacillaceae was observed already
before aGvHD onset. None of the depicted patients had a bacterial
infection recorded during the monitored period. InvSimpson, inverse
Simpson diversity index; hBD2, human beta-defensin 2. (PDF 358 kb)
Additional file 10: Supplementary Discussion. Discussion concerning
survival following high Lactobacillaceae abundances prior to the onset of
aGvHD, and associations of adverse outcomes with Enterococcus
compared with previous studies. (PDF 732 kb)
Additional file 11: R data analysis report 1. Data preparation, filtering
and transformation. (HTML 2337 kb)
Additional file 12: R data analysis report 2. Bacterial alpha-diversity over
time and rank abundance curve for the gut microbiome of HSCT
patients. (HTML 1461 kb)
Additional file 13: R data analysis report 3. Temporal patterns of
immune markers and immune cells in HSCT patients. (HTML 1457 kb)
Additional file 14: R data analysis report 4. Correlations between immune
markers, immune cell counts, and outcomes in HSCT patients. (HTML 1238 kb)
Additional file 15: R data analysis report 5. Variable selection and
multivariate analyses of immune parameters and intestinal bacterial taxa
in HSCT patients. (HTML 2214 kb)
Additional file 16: R data analysis report 6. Clustering of samples into
Community State Types (CSTs) based on Jenson-Shannon divergence.
(HTML 2338 kb)
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Additional file 17: R data analysis report 7. Longitudinal profiles of
microbial community composition and immune markers. (HTML 4520 kb)
Abbreviations
3-IS: 3-indoxyl sulfate; aGvHD: Acute graft-versus-host disease; ALL: Acute
lymphoblastic leukemia; AML: Acute myeloid leukemia; AMP: Antimicrobial
peptide; ATG: Anti-thymocyte globulin; CCpnA: Canonical correspondence
analysis; CRP: C-reactive protein; CST: Community state type; ELISA: Enzyme-
linked immunosorbent assay; GvL effect: Graft-versus-leukemia effect; hBD2/
hBD3: Human beta-defensin 2/3; HLA: Human leukocyte antigen;
HSCT: Hematopoietic stem cell transplantation; IL-6: Interleukin-6; NK
cell: Natural killer cell; OTU: Operational taxonomic unit; P: Patient; PAM
clustering: Partitioning around medoid clustering; QIIME: Quantitative
Insights into Microbial Ecology; SFF: Standard flowgram format; sPLS
regression: Sparse partial least squares regression; TBI: Total body irradiation
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